Wugen: Funding, Investors & Team (Oct 2026)
Wugen is a developer of a novel CAR-T therapy platform intended for T-Cell Malignancies.The company's state-of-the-art gene editing technologies and cutting-edge Car-T cell therapy address some of the challenges that have limited the clinical development of allogeneic Car-T cells, enabling patients aid in the treatment of cancer.
Wugen has raised $322M across 3 funding rounds on record, the most recent a Series C of $35.0M announced in Jul 2026.
That round is above the $8.1M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Wugen Company Profile and Key Stats
Latest funding round on record: Jul 2026.
Wugen Funding Rounds
Wugen raised $172M in a Series B announced in Jul 2021.
4.1 years later, a Series C of $115M was announced in Aug 2025.
11 months later, a Series C of $35.0M was announced in Jul 2026.
Wugen Investors
16 investors are recorded in total; the 5 named above are those the record identifies.
Wugen Founders and Leadership Team
Contact details for the Wugen team: 2 of 4 have an email address on file.
Start 14-day free trial →Wugen Funding Compared to Other Biotechnology Startups
Wugen's latest round of $35.0M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Wugen in Biotechnology and St Louis
Companies Similar to Wugen
Kallyope, we believe that the gut is the gateway to our internal world. Containing millions of neurons, the…
Astrocyte Pharmaceuticals is a drug development company that helps in the recovery and well-being of brain…
Tiny Health offers a gut health test specifically designed for mothers and babies aged 0 to 3 years.…
Junevity is dedicated to using cutting-edge transcription factor medicines to combat age-related diseases.…
Arkea Bio creates technology aimed at reducing greenhouse gas (GHG) emissions in the agricultural sector.
Serán is a contract development and manufacturing organization providing a comprehensive suite of…
Precision’s goal is to provide breakthrough treatments for the one billion patients worldwide suffering from…
Enveda is a biotechnology company that utilizes AI-powered tools to explore and characterize molecules from…
Avery Therapeutics, Inc. is a company dedicated to developing tissue engineered therapeutics to treat…
Circle Pharma is a biotechnology company in the initial stages of development that uses unique computational…
Evvy is for people with vaginas who want to be empowered with information about their microbiome. Their…
Wugen Funding FAQs
What does Wugen do?
Wugen is a developer of a novel CAR-T therapy platform intended for T-Cell Malignancies.The company's state-of-the-art gene editing technologies and cutting-edge Car-T cell therapy address some of the challenges that have limited the clinical development of allogeneic Car-T cells, enabling patients aid in the treatment of cancer.
How much funding has Wugen raised?
Wugen has raised $322M across 3 rounds on record. The most recent is a Series C of $35.0M announced in Jul 2026.
When did Wugen last raise funding?
Wugen's most recent funding round on record is a Series C of $35.0M, announced in Jul 2026.
Who has invested in Wugen?
Investors on record for Wugen include Sands Capital Ventures, Alpha Wave Global, Intermediate Capital Group, Fidelity, Abingworth. FundedIQ records 16 investors in total.
Who founded Wugen?
FundedIQ lists Matthew Cooper (Founder) at Wugen.
Who is the CEO of Wugen?
Kumar is listed as Chief Executive Officer at Wugen.
Where is Wugen headquartered?
Wugen is based in St Louis, Missouri, United States.
How many employees does Wugen have?
Wugen is in the 11-50 employee band.
When was Wugen founded?
Wugen was founded in 2018.
How does Wugen's funding compare to other Biotechnology startups?
Wugen's latest round of $35.0M is above the $8.1M median round size for Biotechnology companies on FundedIQ across 4,185 tracked companies over the last two years.
About FundedIQ's Wugen Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Wugen is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.